[Treatment of superficial tumors and carcinomas in situ of the bladder by intravesical BCG therapy].

89 patients with a superficial tumor of the bladder were treated with intravesical BCG: 150 mg of the Pasteur strain was instilled once a week for 6 weeks, once every other week for 3 months and once a month for 2 years, in 4 groups of patients. Group I: 20 patients with primary carcinoma in situ (CIS); 18 have been monitored for more than 6 months: in each, cytology has become negative; 16 were controlled by TUR: in all but one complete regression of CIS was observed. Group II: 24 patients with stage O tumor; in 16, follow up is greater than 12 months : the recurrence rate dropped from 11.12/100 months patients to 1.52/100 months patients. Group III: 12 patients with stage A tumor: in 10, follow up is greater than 12 months; 2 patients had tumor recurrence. Group IV: 28 patients with stage O or stage A tumor associated with CIS; in 17, followup is greater than 12 months: CIS disappeared in 13, but in 2 recurrences were observed (stage O without CIS). In addition to irritative side effects on the bladder, we observed complications in four cases: epididymitis in 2 patients and BCG spread with granulomatous hepatitis and bronchopulmonary lesions in two others.